In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
[Clinical Medicine Insights: Oncology] This research examines the role of adjuvant chemotherapy in resectable bile duct cancer treatment.
People who took aspirin on a regular basis were three times less likely to develop the disease.
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer.
Patients with bile duct cancer could be helped by a new class of experimental drug, according to a study.
Nonsignificant improvement in unselected patients, but significant benefit for high-risk patients.
Results from three new studies are consistent with earlier findings that aspirin can reduce cancer risk and, in some cases, metastasis.
Aspirin use lowers the risk of esophageal, gastric, biliary, and breast cancer and reduces distant metastases.
Patients with advanced biliary cancer treated with cisplatin plus gemcitabine experience a significant survival advantage without added toxicity, according to a study published in The New England Journal of Medicine (2010;362(14):1273-1281).
